Sequencing-based noninvasive prenatal tests that screen for aneuploidies such as Down syndrome and Edwards syndrome are rapidly becoming part of clinical care, especially for women at elevated risk for fetal aneuploidies.

While these tests in general have very high sensitivities and specificities, one factor that physicians and providers of the test are finding to be important for accuracy is the amount of fetal DNA present in the maternal plasma, with false negatives often occurring in samples with low amounts of fetal DNA.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: the Human Silencing Hub protein complex, and more.

Heads of various research funding agencies discuss how to encourage scientific breakthroughs, ScienceInsider reports.

The Kansas City Star examines issues surrounding newborn genome sequencing.

Researchers say their Research Resource Identifier citation format is catching on, Nature News reports.